Sub menu

 

 

Guideline on clinical investigation of medicinal products, including depot preparations in the treatment of schizophrenia

We have adopted this International Scientific Guideline - EMA/CHMP/40072/2010 Rev. 1.

Last updated

About this guideline

Overseas effective date:  1 April 2013

Replaces: CPMP/EWP/559/95. Note for Guidance on the Clinical Investigation of Medicinal Products in the Treatment of Schizophrenia  (adopted by TGA 1 May 2000)and CPMP/EWP/49/01.

Categories: Clinical efficacy and safety | Nervous system

TGA annotations: Nil

  • Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
  • All documents and other content published by the European Medicines Agency (EMA) on this website are under the copyright and other intellectual property rights ownership of the EMA. Please refer to Legal notice | European Medicines Agency - external site for further information.

For more information see International scientific guidelines adopted in Australia.

Topics

Help us improve this page

This form is anonymous. If you would like a response from us, please visit Contact us.